Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding

• Status: Unknown status
• Trial end date: 2018-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Zhongshan Hospital
• Collaborators: Beijing Ditan Hospital; Renmin Hospital of Wuhan University; Second Hospital of Lanzhou University; Shandong Provincial Hospital; The First Affiliated Hospital of Anhui Medical University; The Second People's Hospital of Lanzhou; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
• Treatments: Rifamycins; Rifaximin

Criteria

Inclusion Criteria:

• 18 y.o. ≤age≤75 y.o.;

• Cirrhotic gastroesophageal variceal bleeding underwent endoscopic treatment (include esophageal varices ligation, endoscopic injection sclerosis and gastric N-butyl-cyanoacrylate injection).

Exclusion Criteria:

• age <18 y.o. or age > 75 y.o.;

• Never had the variceal bleeding episode before;

• Do not have endoscopic treatment;

• combined with other malignant tumor (not exclude patients with hepatocellular carcinoma who don't not need treatment at the moment);

• Known infection after endoscopic treatment (Fever, microbial cultures positive, et al.)

• Massive ascites or combined with other high risk factor that require prophylaxis use of antibiotics.

• Acute variceal bleeding within 5 days.

• Use of other antibiotics in the past 2 weeks;

• Refuse to participate